Kenichi Kamata

Kenichi Kamata

Auto-generated profile, based on publicly available information

Kenichi Kamata

Nihon University 1-5-1 Kandasurugadai, Chiyoda-ku

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DTDaiki Terada
Daiki Terada
AVArnout R. D. Voet
Arnout R. D. Voet
HNHiroki Noguchi
Hiroki Noguchi
KKKenichi Kamata
Kenichi Kamata
MOMio Ohki
Mio Ohki
KZKam Y. J. Zhang
Kam Y. J. Zhang
Computational protein design has advanced very rapidly over the last decade, but there remain few examples of artificial proteins with direct medical applications. This study describes a new artificialβ-trefoil lectin that recognises Burkitt’s lymphoma cells, and which was designed with the intention of finding a basis for novel cancer treatments or diagnostics. The new protein, called “Mitsuba”, is based on the structure of the natural shellfish lectin MytiLec-1, a member of a small lectin family that uses unique sequence motifs to bindα-D-galactose. The three subdomains of MytiLec-1 each carry one galactose binding site, and the 149-residue protein forms a tight dimer in solution. Mitsuba (meaning “three-leaf” in Japanese) was created by symmetry constraining the structure of a MytiLec-1 subunit, resulting in a 150-residue sequence that contains three identical tandem repeats. Mitsuba-1 was expressed and crystallised to confirm the X-ray structure matches the predicted model. Mitsuba-1 recognises cancer cells that express globotriose (Galα(1,4)Galβ(1,4)Glc) on the surface, but the cytotoxicity is abolished.

24 August 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
LVLaurens Vandebroek
Laurens Vandebroek
HNHiroki Noguchi
Hiroki Noguchi
KKKenichi Kamata
Kenichi Kamata
JTJeremy R. H. Tame
Jeremy R. H. Tame
LMLuc Van Meervelt
Luc Van Meervelt
AVArnout R. D. Voet
Arnout R. D. Voet
Novel bioinorganic hybrid materials based on proteins and inorganic clusters have enormous potential for the development of hybrid catalysts that synergistically combine properties of both materials. Here we report the creation of hybrid assemblies between a computationally designed symmetrical protein Pizza6-S and different polyoxometalates with matching symmetry: the tellurotungstic Anderson-Evans (Na6[TeW6O24]·22H2O) (TEW); Keggin (H4[SiW12O40]·6H2O) (STA); and 1 : 2 CeIII-substituted Keggin (K11[CeIII[PW11O39]2]·20H2O) (Ce-K). This results in the formation of complexes with clearly defined stoichiometries in solution. Crystal structures validate the complexes as building blocks for the formation of larger assemblies.

26 November 2019 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
Yuki FujiiYuki Fujii
Yuki Fujii
Marco GerdolMarco Gerdol
Marco Gerdol
Sarkar M.A. KawsarSarkar M.A. Kawsar
Sarkar M.A. Kawsar
Imtiaj HasanImtiaj Hasan
Imtiaj Hasan
FSFrancesca Spazzali
Francesca Spazzali
Yasuhiro OzekiYasuhiro Ozeki
Yasuhiro Ozeki
A 15‐kDa lectin, termed SeviL, was isolated from Mytilisepta virgata (purplish bifurcate mussel). SeviL forms a noncovalent dimer that binds strongly to ganglio‐series GM1b oligosaccharide (Neu5Acɑ2‐3Galβ1‐3GalNAcβ1‐4Galβ1‐4Glc) and its precursor, asialo‐GM1 (Galβ1‐3GalNAcβ1‐4Galβ1‐4Glc). SeviL also interacts weakly with the glycan moiety of SSEA‐4 hexaose (Neu5Acα2‐3Galβ1‐3GalNAcβ1‐3Galα1‐4Galβ1‐4Glc). A partial protein sequence of the lectin was determined by mass spectrometry, and the complete sequence was identified from transcriptomic analysis. SeviL, consisting of 129 amino acids, was classified as an R(icin B)‐type lectin, based on the presence of the QxW motif characteristic of this fold. SeviL mRNA is highly expressed in gills and, in particular, mantle rim tissues. Orthologue sequences were identified in other species of the family Mytilidae, including Mytilus galloprovincialis, from which lectin MytiLec‐1 was isolated and characterized in our previous studies. Thus, mytilid species contain lectins belonging to at least two distinct families (R‐type lectins and mytilectins) that have a common β‐trefoil fold structure but differing glycan‐binding specificities. SeviL displayed notable cytotoxic (apoptotic) effects against various cultured cell lines (human breast, ovarian, and colonic cancer; dog kidney) that possess asialo‐GM1 oligosaccharide at the cell surface. This cytotoxic effect was inhibited by the presence of anti‐asialo‐GM1 oligosaccharide antibodies. With HeLa ovarian cancer cells, SeviL showed dose‐ and time‐dependent activation of kinase MKK3/6, p38 MAPK, and caspase‐3/9. The transduction pathways activated by SeviL via the glycosphingolipid oligosaccharide were triggered apoptosis. Database Nucleotide sequence data have been deposited in the GenBank database under accession numbers MK434191, MK434192, MK434193, MK434194, MK434195, MK434196, MK434197, MK43419 8, MK434199, MK434200, and MK434201.

28 April 2020 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
BMBram Mylemans
Bram Mylemans
ILIna Laier
Ina Laier
KKKenichi Kamata
Kenichi Kamata
SASatoko Akashi
Satoko Akashi
HNHiroki Noguchi
Hiroki Noguchi
AVArnout R. D. Voet
Arnout R. D. Voet
β‐propeller proteins are common in nature, where they are observed to adopt 4‐ to 10‐fold internal rotational pseudosymmetry. This size diversity can be explained by the evolutionary process of gene duplication and fusion. In this study we investigated a distorted β‐propeller protein, an apparent intermediate between two symmetries. From this template, we created a perfectly symmetric 9‐bladed β‐propeller named Cake, using computational design and ancestral sequence reconstruction. The designed repeat sequence was found to be capable of generating both 8‐fold and 9‐fold propellers which are highly stable. Cake variants with 2 to 10 identical copies of the repeat sequence were characterized by X‐ray crystallography and in solution. They were found to be highly stable, and to self‐assemble into 8‐ or 9‐ fold symmetrical propellers. These findings show that the β‐propeller fold allows sufficient structural plasticity to permit a given blade to assemble different forms, a transition from even to odd changes in blade number, and provide a potential explanation for the wide diversity of repeat numbers observed in natural propeller proteins.

31 August 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
RHRyuhei Hayashi
Ryuhei Hayashi
KKKenichi Kamata
Kenichi Kamata
Marco GerdolMarco Gerdol
Marco Gerdol
Yuki FujiiYuki Fujii
Yuki Fujii
THTakashi Hayashi
Takashi Hayashi
Yasuhiro OzekiYasuhiro Ozeki
Yasuhiro Ozeki
We here report the purification of a novel member of the galectin family, the β-galactoside-binding lectin hRTL, from the marine sponge Chondrilla australiensis. The hRTL lectin is a tetrameric proto-type galectin with a subunit molecular weight of 15.5 kDa, consisting of 141 amino acids and sharing 92% primary sequence identity with the galectin CCL from the congeneric species C. caribensis. Transcriptome analysis allowed for the identification of additional sequences belonging to the same family, bringing the total number of hRTLs to six. Unlike most other galectins, hRTLs display a 23 amino acid-long signal peptide that, according to Erdman degradation, is post-translationally cleaved, leaving an N-terminal end devoid of acetylated modifications, unlike most other galectins. Moreover, two hRTLs display an internal insertion, which determines the presence of an unusual loop region that may have important functional implications. The characterization of the glycan-binding properties of hRTL revealed that it had high affinity towards TF-antigen, sialyl TF, and type-1 N-acetyl lactosamine with a Galβ1-3 structure. When administered to DLD-1 cells, a colorectal carcinoma cell line expressing mucin-associated TF-antigen, hRTL could induce glycan-dependent cytotoxicity.

5 July 2025 in Epilepsia
Verified
Journal Article
Open access
KTKarin Thevissen
Karin Thevissen
ANAnnelii Ny
Annelii Ny
DCDaniëlle Copmans
Daniëlle Copmans
JTJana Tits
Jana Tits
KKKenichi Kamata
Kenichi Kamata
PWPeter de Witte
Peter de Witte
Objective: Drug‐resistant epilepsy (DRE) affects >25 million people worldwide and is often associated with neuroinflammation. Increasing evidence links deficiency or malfunctioning of the enzyme phosphoglycerate dehydrogenase (PHGDH), which converts 3‐phosphoglycerate to generate serine and the neurotransmitter glycine, with (drug‐resistant) epilepsy. Moreover, PHGDH, which is primarily expressed in astrocytes within the brain, has been identified as a critical enzyme in driving macrophage polarization toward an anti‐inflammatory state. Hence, PHGDH activators may be beneficial for treating DRE by exhibiting both antiseizure and anti‐inflammatory activity. The objective of this study was to identify such PHGDH activators. Methods: We screened a drug repurposing library for PHGDH activators and assessed their antiseizure and anti‐inflammatory properties using various zebrafish and mouse epilepsy models and explored the mechanistic consequences of activating PHGDH in a cell line, in astrocytes, and in zebrafish heads. Finally, we assessed the efficacy of clioquinol as add‐on treatment in three severe DRE patients in a clinical open pilot proof‐of‐concept study. Results: We identified haloquinolines from a drug repurposing library as potent activators of PHGDH. The most promising haloquinoline clioquinol can increase the catalytic activity of PHGDH up to 2.5‐fold, thereby increasing de novo glycine biosynthesis and resulting in reduced glutamate levels. Moreover, we show that clioquinol has PHGDH‐dependent antiseizure activity as well as anti‐inflammatory properties in vivo using various zebrafish and mouse epilepsy models. Finally, we demonstrate the efficacy of clioquinol as add‐on treatment in severe DRE patients; two patients showed a 37%–47% reduction in seizure frequency, and all three patients noted a positive impact on quality of life and seizure severity. Significance: Increasing activity of PHGDH is a promising new approach to treat DRE.